drugset / Trial / NCT03748758

Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

NCT03748758

Phase 1 Completed 30 enrolled Novus Therapeutics, Inc
RandomizedParallel-groupQuadruple-blindOther

Summary

The purpose of this study is to evaluate the safety and tolerability of two dose levels of OP0201 and placebo, when administered intranasally in healthy adults subjects.

Timeline

Start
2018-11-27
Primary completion
2019-03-20
Completion
2019-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject OP0201 Unknown 30 mg Intranasal
Subject OP0201 Unknown 60 mg Intranasal

Indications

No indication recorded.